TY - JOUR
T1 - Global brain glucose uptake on 18F-FDG-PET/CT is influenced by chronic cardiovascular risk
AU - Borja, Austin J
AU - Hancin, Emily C
AU - Zhang, Vincent
AU - Koa, Benjamin
AU - Bhattaru, Abhijit
AU - Rojulpote, Chaitanya
AU - Detchou, Donald K
AU - Aly, Mahmoud
AU - Kaghazchi, Fatemeh
AU - Gerke, Oke
AU - Patil, Shivaraj
AU - Gonuguntla, Karthik
AU - Werner, Thomas J
AU - Revheim, Mona-Elisabeth
AU - Høilund-Carlsen, Poul F
AU - Alavi, Abass
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Purpose The goal of this study was to assess global cerebral glucose uptake in subjects with known cardiovascular risk factors by employing a quantitative
18F-fluorodeoxyglucose-PET/computed tomography (FDG-PET/CT) technique. We hypothesized that at-risk subjects would demonstrate decreased global brain glucose uptake compared to healthy controls. Methods We compared 35 healthy male controls and 14 male subjects at increased risk for cardiovascular disease (CVD) as assessed by the systematic coronary risk evaluation (SCORE) tool. All subjects were grouped into two age-matched cohorts: younger (<50 years) and older (≥50 years). The global standardized uptake value mean (Avg SUV
mean) was measured by mapping regions of interest of the entire brain across the supratentorial structures and cerebellum. Wilcoxon's rank-sum test was used to assess the differences in Avg SUV
meanbetween controls and at-risk subjects. Results Younger subjects demonstrated higher brain Avg SUV
meanthan older subjects. In addition, in both age strata, the 10-year risk for fatal CVD according to the SCORE tool was significantly greater in the at-risk groups than in healthy controls (younger: P = 0.0304; older: P = 0.0436). In the younger cohort, at-risk subjects demonstrated significantly lower brain Avg SUV
meanthan healthy controls (P = 0.0355). In the older cohort, at-risk subjects similarly had lower Avg SUV
meanthan controls (P = 0.0343). Conclusions Global brain glucose uptake appears to be influenced by chronic cardiovascular risk factors. Therefore, FDG-PET/CT may play a role in determining the importance of CVD on brain function and has potential for monitoring the efficacy of various therapeutic interventions.
AB - Purpose The goal of this study was to assess global cerebral glucose uptake in subjects with known cardiovascular risk factors by employing a quantitative
18F-fluorodeoxyglucose-PET/computed tomography (FDG-PET/CT) technique. We hypothesized that at-risk subjects would demonstrate decreased global brain glucose uptake compared to healthy controls. Methods We compared 35 healthy male controls and 14 male subjects at increased risk for cardiovascular disease (CVD) as assessed by the systematic coronary risk evaluation (SCORE) tool. All subjects were grouped into two age-matched cohorts: younger (<50 years) and older (≥50 years). The global standardized uptake value mean (Avg SUV
mean) was measured by mapping regions of interest of the entire brain across the supratentorial structures and cerebellum. Wilcoxon's rank-sum test was used to assess the differences in Avg SUV
meanbetween controls and at-risk subjects. Results Younger subjects demonstrated higher brain Avg SUV
meanthan older subjects. In addition, in both age strata, the 10-year risk for fatal CVD according to the SCORE tool was significantly greater in the at-risk groups than in healthy controls (younger: P = 0.0304; older: P = 0.0436). In the younger cohort, at-risk subjects demonstrated significantly lower brain Avg SUV
meanthan healthy controls (P = 0.0355). In the older cohort, at-risk subjects similarly had lower Avg SUV
meanthan controls (P = 0.0343). Conclusions Global brain glucose uptake appears to be influenced by chronic cardiovascular risk factors. Therefore, FDG-PET/CT may play a role in determining the importance of CVD on brain function and has potential for monitoring the efficacy of various therapeutic interventions.
KW - F-fluorodeoxyglucose
KW - PET/computed tomography
KW - atherosclerosis
KW - cardiovascular disease
KW - vascular dementia
U2 - 10.1097/MNM.0000000000001349
DO - 10.1097/MNM.0000000000001349
M3 - Journal article
C2 - 33323870
VL - 42
SP - 444
EP - 450
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
SN - 0143-3636
IS - 4
ER -